Skip to main content
OpenTrials
Completed

NCT Number: NCT06391437

Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes

Aim of the work is to assess the prevalence of vitamin A deficiency in critically ill children with sepsis and the association between vitamin A deficiency and clinical outcomes

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–16 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Benha University Hospital

Cairo, 13511, Egypt

About this study

Vitamin A plays an essential role in a large number of physiological functions that encompass vision, growth, reproduction, hematopoiesis, and immunity.

Despite major advances in the knowledge of vitamin A biology, its deficiency is still a serious public health problem that affects an estimated 127 million preschool children. In children, vitamin A deficiency results in increased risks of mortality and morbidity from infections, blindness and anemia. Many of these effects can be linked to the immunological functions of vitamin A.

Vitamin A modulates immunity through its active metabolite retinoic acid (RA), which acts on retinoid receptors in various cell types. Studies utilizing various animal models of vitamin A or retinoid receptor deficiency have revealed an integral role for RA in immunity and tolerance.

Retinoic acid (RA) has been reported to promote anti-inflammatory regulatory T cell (Treg) differentiation and inhibit interleukin (IL)-6-induced proinflammatory T helper 17 (Th17) cells, which could balance pro- and anti-inflammatory immunity.

Vitamin A deficiency (VAD ) is associated with adverse health outcomes due to an increased risk of infection in children. VAD could impact immunity at multiple levels, including disturbing the integrity of the gastrointestinal mucosal barrier, decreasing monocyte and natural killer (NK) cell numbers, and impairing the function of macrophages, dendritic cells, and neutrophils.

Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, contributes to millions of deaths worldwide each year, with a mortality rate of more than 25%. Remarkably, sepsis is a common cause of death in children. The mortality of severe sepsis was reported to be as high as 34.6% in children.

As a public health problem, sepsis has posed a significant burden on extensive health care resources for many years. It is reported as a complicated immune disorder characterized by both a hyperinflammatory immune response in the early stage and immunosuppression in the later stage.

Most deaths from sepsis occur due to opportunistic pathogen superinfections or latent viral reactivation resulting from immunosuppression.

VA is an immunomodulatory, and its deficiency may cause an imbalance between pro- and anti-inflammatory factors and impaired immune function, which are found in sepsis. There is a biological rationale that VAD may be a contributing factor related to poor clinical outcomes in patients with sepsis. Importantly, VAD is highly prevalent in children, especially in preschool children. However, there is limited data regarding the correlation between VAD and sepsis, so we hypothesize that VAD may play an important role in the pathogenesis and progression of sepsis in children.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All pediatric Patients from 29 days to 16 years old who were admitted to the pediatric intensive care unit (PICU) with sepsis as defined by International pediatric sepsis consensus conference will be consecutively recruited in this study.

Sex- and age-matched approximate-health children without sepsis will be recruited as a control group.

Exclusion criteria

  • - Age > 16 years old.
  • - Premature infants and low birth weight infants.
  • - Children with underlying organ dysfunction, having received chemotherapy or radiotherapy, hematological malignancies, primary or acquired immunodeficiency.
  • - Children who discharged against medical advice with an uncertain prognosis.

Treatment and study plan

Extraction of blood sample

Diagnostic Test

Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.

Primary outcomes

  1. Severity of sepsis in pediatric patients with vitamin A deficiency

    Time frame: 1 month

    Severity of sepsis in pediatric patients with vitamin A deficiency

  2. Clinical outcomes in septic pediatric patients with vitamin A deficiency

    Time frame: 1 month

    Length of hospital stay and mortality rate in pediatric patients with vitamin A deficiency

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 30, 2024
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.